Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $21.7 million in its first quarter. On a per-share basis, the Princeton, New Jersey-based ...

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

Learn more about whether Amicus Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going ...

Analysts are estimating that Amicus Therapeutics will report an earnings per share (EPS) of $0.08. The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of ...

We expect investors to focus on the sales performance of Amicus Therapeutics’ FOLD lead marketed drug, Galafold (migalastat), ...

The rare disease-focused biotech company posted adjusted earnings per share of $0.03, surpassing the analyst consensus estimate of -$0.02. However, revenue of $125.25 million missed Wall Street’s ...